Key Considerations For Selecting Packaging Solutions For Cell And Gene Therapies

By Tara Haarlander, West Pharmaceutical Services, Inc.

The astounding growth and development we have witnessed in the cell and gene therapy industry over the last decade is bringing life-changing therapies to the patients who have been so anxiously awaiting them.

At the same time, as with any new drug class, challenges that may not have been considered during the drug development phase may suddenly show up and stand in the way of overcoming that last hurdle: packaging and delivering your precious new molecule to the patient.

A therapy that involves cells or genes is a very different beast from a small molecule, a peptide, or even a protein therapy. You must think about the special needs early and often in order to safeguard it all the way from development until it reaches the patient. Doing so will minimize your risk of not meeting timelines or staying within budget, and most importantly, it will minimize risks to the safety and efficacy of your gene therapy drug product from the bench to the patient.

In this article, explore the risks of not considering packaging early and often and what sets Crystal Zenith apart for cell and gene therapies.